

Supplementary Online Content

Ahmady S, Jansen MHE, Nelemans PJ, et al. Risk of invasive cutaneous squamous cell carcinoma after different treatments for actinic keratosis: a secondary analysis of a randomized clinical trial. *JAMA Dermatol*. Published online April 27, 2022.
doi:10.1001/jamadermatol.2022.1034

eTable. Cumulative Probability of cSCC 1 and 4 Years Post-Treatment and Hazard Ratios for Developing cSCC in the Treated Area

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable. Cumulative Probability of cSCC 1 and 4 Years Post-Treatment and Hazard Ratios for Developing cSCC in the Treated Area

	Cumulative probability of cSCC, % (95% CI)		Hazard ratio (95% CI)	P-value
	During 1 year after end treatment	During 4 years after end treatment		
Intention-to-treat				
5-fluorouracil	0.7 (0.1–4.6)	2.2 (0.7–6.6)	1	
Imiquimod	1.9 (0.6–5.9)	5.8 (2.9–11.3)	2.58 (0.81–8.26)	0.110
MAL-PDT	1.3 (0.3–5.1)	3.6 (1.5–8.6)	1.48 (0.42–5.26)	0.545
Ingenol mebutate	0.6 (0.1–4.5)	3.0 (1.1–7.9)	1.35 (0.38–4.79)	0.647
Per-protocol				
5-fluorouracil	0.6 (0.1–4.5)	2.1 (0.7–6.4)	1	
Imiquimod	2.0 (0.6–6.0)	5.8 (2.9–11.3)	2.21 (0.75–6.51)	0.150
MAL-PDT	1.3 (0.3–5.2)	3.7 (1.5–8.8)	1.07 (0.31–3.71)	0.912
Ingenol mebutate	0.6 (0.1–4.5)	3.0 (1.1–7.9)	1.17 (0.36–3.85)	0.793